SCHEDULE 13G/A: Panacea Venture Amends Adagene Inc. Stake to 3.8%
Beneficial Ownership Amendment
Panacea Venture Healthcare Fund II and related entities have filed an Amendment No. 3 to their Schedule 13G, disclosing a 3.8% beneficial ownership in Adagene Inc. as of September 30, 2025.
Summary
- Panacea Venture Healthcare Fund II, L.P., Panacea Venture Healthcare Fund II GP Company, Ltd., Panacea Innovation Limited, and James Huang collectively reported beneficial ownership of 2,250,000 Ordinary Shares of Adagene Inc.
- This ownership represents 3.8% of Adagene Inc.'s Ordinary Shares outstanding.
- The calculation is based on 58,914,087 Ordinary Shares outstanding as of June 30, 2025, as disclosed in Adagene Inc.'s F-3 Registration Statement filed on October 31, 2025.
- The reporting persons share both voting and dispositive power over the 2,250,000 shares.
- James Huang is the sole owner of Panacea Innovation Limited, which in turn solely owns Panacea Venture Healthcare Fund II GP Company, Ltd., the general partner of Panacea Venture Healthcare Fund II, L.P.
Sentiment
Score: 5
Explanation: The filing is a routine regulatory disclosure of beneficial ownership, indicating a passive investment below the 5% threshold. It does not inherently convey positive or negative sentiment regarding the issuer's performance or future prospects.
Positives
- NA
Negatives
- NA
Risks
- The filing itself does not detail specific risks related to Adagene Inc.'s operations or financial health, as it is a disclosure of beneficial ownership.
Future Outlook
This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Adagene Inc.'s future performance or the reporting persons' investment strategy beyond the current ownership disclosure.
Industry Context
This filing is a routine disclosure by an institutional investor, Panacea Venture, indicating a passive investment in Adagene Inc. It reflects a standard regulatory requirement for investors holding less than 5% of a company's outstanding shares and not seeking to influence control. Such filings provide transparency on significant ownership stakes within the biotechnology or healthcare sector, where Adagene Inc. operates.
Comparison to Industry Standards
- NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's passive stake in Adagene Inc., confirming a stable ownership structure without intent to influence control.
- Regulatory Authorities: Fulfills SEC disclosure requirements for beneficial ownership, ensuring market transparency.
Key Dates
| Date | Description |
|---|---|
| 2025-06-30 | Date as of which 58,914,087 Ordinary Shares of Adagene Inc. were outstanding, as disclosed in the Issuer's F-3 Registration Statement. |
| 2025-09-30 | Date of event which required the filing of this Schedule 13G Amendment No. 3, representing the measurement date for beneficial ownership. |
| 2025-10-31 | Date Adagene Inc. filed its F-3 Registration Statement with the SEC. |
| 2025-11-14 | Date the Schedule 13G Amendment No. 3 was signed by the reporting persons. |
Keywords
Adagene Inc., Panacea Venture, Schedule 13G, Beneficial Ownership, Ordinary Shares, Institutional Investor, SEC Filing, Investment Disclosure
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.